SALT LAKE CITY, July 22, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new results from its second human clinical study on the MindBody GLP-1 System , revealing even more compelling outcomes across a broader participant base
ADAM10mediated ephrinB2 shedding promotes myofibroblast activation and organ fibrosis
The demand for glucagon-like peptide-1 (GLP-1) medications like Wegovy, Ozempic, Zepbound, and Mounjaro has surged in recent years, driven by their effectiveness for weight loss, blood sugar control, and the reduction of major cardiovascular events
Contact us today to schedule a consultation and take the first steps toward a healthier, happier you